388 related articles for article (PubMed ID: 34370634)
1. Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design.
Ugbaja SC; Lawal IA; Kumalo HM; Lawal MM
Curr Drug Targets; 2022; 23(3):266-285. PubMed ID: 34370634
[TBL] [Abstract][Full Text] [Related]
2. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
3. Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer's Disease Therapy.
Ugbaja SC; Lawal IA; Abubakar BH; Mushebenge AG; Lawal MM; Kumalo HM
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889246
[TBL] [Abstract][Full Text] [Related]
4. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
[TBL] [Abstract][Full Text] [Related]
5. In silico screening of potential β-secretase (BACE1) inhibitors from VIETHERB database.
Nhung NT; Duong N; Phung HTT; Vo QV; Tam NM
J Mol Model; 2022 Feb; 28(3):60. PubMed ID: 35156141
[TBL] [Abstract][Full Text] [Related]
6. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
7. An Overview of β-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor.
Ugbaja SC; Lawal MM; Kumalo HM
Curr Med Chem; 2022; 29(1):114-135. PubMed ID: 34102967
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
9. Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimer's: A Review.
Munj SM; Patil PB
Curr Top Med Chem; 2023; 23(2):77-97. PubMed ID: 36579387
[TBL] [Abstract][Full Text] [Related]
10. The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease.
Shah H; Patel A; Parikh V; Nagani A; Bhimani B; Shah U; Bambharoliya T
CNS Neurol Disord Drug Targets; 2020; 19(3):184-194. PubMed ID: 32452328
[TBL] [Abstract][Full Text] [Related]
11. Acylguanidine-BACE1 complex: Insights of intermolecular interactions and dynamics.
Saravanan K; Kumaradhas P
J Theor Biol; 2019 Mar; 464():33-49. PubMed ID: 30571961
[TBL] [Abstract][Full Text] [Related]
12. The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
Youn K; Park JH; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2016 Oct; 8(10):. PubMed ID: 27754406
[TBL] [Abstract][Full Text] [Related]
13. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach.
Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K
J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924
[TBL] [Abstract][Full Text] [Related]
14. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
16. Structural and molecular insights into tacrine-benzofuran hybrid induced inhibition of amyloid-β peptide aggregation and BACE1 activity.
Kaur R; Narang SS; Singh P; Goyal B
J Biomol Struct Dyn; 2023; 41(22):13211-13227. PubMed ID: 37013977
[TBL] [Abstract][Full Text] [Related]
17. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
Evin G; Hince C
Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
[TBL] [Abstract][Full Text] [Related]
18. Identification of new BACE1 inhibitors for treating Alzheimer's disease.
Kushwaha P; Singh V; Somvanshi P; Bhardwaj T; Barreto GE; Ashraf GM; Mishra BN; Chundawat RS; Haque S
J Mol Model; 2021 Jan; 27(2):58. PubMed ID: 33517514
[TBL] [Abstract][Full Text] [Related]
19. Determining Structural Changes for Ligand Recognition between Human and Rat Phosphorylated BACE1
Velazquez Toledano J; Bello M; Correa Basurto J; Guerrero González I; Pacheco-Yépez J; Rosales Hernández MC
ACS Chem Neurosci; 2024 Feb; 15(3):629-644. PubMed ID: 38227464
[TBL] [Abstract][Full Text] [Related]
20. Repurposing of phyto-ligand molecules from the honey bee products for Alzheimer's disease as novel inhibitors of BACE-1: small molecule bioinformatics strategies as amyloid-based therapy.
Nisa N; Rasmita B; Arati C; Uditraj C; Siddhartha R; Dinata R; Bhanushree B; Bidanchi RM; Manikandan B; Laskar SA; Abinash G; Pori B; Roy VK; Gurusubramanian G
Environ Sci Pollut Res Int; 2023 Apr; 30(17):51143-51169. PubMed ID: 36808033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
